Loading...
NPI 1588757033 · Brooklyn, NY · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Enigma Management Corp Dba Alliance Laboratory is a clinical medical laboratory provider located in Brooklyn, New York. This profile covers 100 Medicare and 159 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Enigma Management Corp Dba Alliance Laboratory |
| Address | 3611 14th Ave |
| City | Brooklyn |
| State | NY |
| ZIP | 11218 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | October 2, 2006 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $28.3M |
| Medicaid | $3.9M |
ENIGMA MANAGEMENT CORP DBA ALLIANCE LABORATORY is a clinical medical laboratory with a long enrollment history (NPI enumerated 2006-10-02, ~20 years ago), indicating established operations and sustained participation in federal and state programs. The provider’s Medicare lifetime revenue is $28.3M while Medicaid lifetime revenue is $3.9M, showing a markedly larger Medicare footprint by scale.
Revenue is highly concentrated on Medicare: the precomputed top 3 Medicare codes account for 97.9% of the provider’s Medicare revenue, and a single code, K1034, generates $27.8M (97.1% of Medicare revenue). This concentration signals that Medicare receipts are overwhelmingly dependent on provision of the service described by K1034 (provision of nonprescription self-administered COVID-19 tests).
Medicaid revenue is also concentrated but less extremely: the top 3 Medicaid codes account for 73.2% of Medicaid revenue. That Medicaid top-three mix is dominated by G0483 ($1.3M, 35.0% of Medicaid revenue) and U0003 ($1.1M, 31.8% of Medicaid revenue), with U0005 contributing $228.2K (6.4% of Medicaid revenue), indicating a Medicaid business driven by definitive drug testing and high-volume SARS‑CoV‑2 nucleic acid testing.
The provider’s competitive standing is uneven across payers and codes. For K1034 the provider ranks #9 of 30143 providers nationally (100th percentile) and is labeled an extreme outlier, reflecting an outsized national role in billing that specific COVID self-test code; by contrast, many other high-volume Medicare codes (for example, G0483 at $111.1K and 81162 at $110.9K) represent only small shares of total Medicare revenue and rank in middle or lower percentiles nationally.
State-level Medicaid rankings show stronger regional competitiveness for services other than K1034: G0483 ranks #4 of 34 providers in-state (91th percentile) and U0003 ranks #44 of 336 providers in-state (87th percentile), which together indicate a meaningful in-state presence for definitive drug testing and molecular COVID testing. Several Medicaid codes tied to respiratory and multiplex viral testing (87631, 87635, 87633) and specimen collection (G2023) also appear in the top list, supporting the view of a lab with substantial infectious-disease testing throughput in-state.
The provider’s service mix combines mass-volume COVID testing (K1034, U0003, U0005, G2023) with specialized laboratory services such as definitive drug testing (G0483) and targeted genetic tests (for example, 81162, 81226, 81225). However, these specialized and routine clinical chemistry/hematology panels (multiple CPTs listed with relatively small dollar contributions versus the K1034 line) contribute only modest revenue shares on Medicare and Medicaid, underscoring that the business model is currently dominated by high-volume infectious-disease and drug-testing lines.
From a payer-risk and contracting perspective, Medicare exposure is concentrated and therefore sensitive to changes in reimbursement or coding for K1034 and the small set of top codes (top 3 Medicare codes = 97.9% of Medicare revenue). Medicaid exposure is more diversified but still heavily weighted toward three codes (top 3 Medicaid codes = 73.2% of Medicaid revenue), so payers should treat both lines as concentrated but recognize the particularly acute Medicare concentration around K1034.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
100 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | 2,315,210 | $10 | $27.8M |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 460 | $240 | $111.1K |
| 81162 | The lab analyst performs the technical lab test to analyze the entire gene sequence for the BRCA1, DNA repair–associated gene, also called BRCA1; and BRCA2, DNA repair–associated gene, also called… | 60 | $1,790 | $110.9K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 1,470 | $70 | $109K |
| 87631 | The lab analyst performs the technical steps to detect three to five types or subtypes of pathogens, such as adenovirus, influenza virus, coronavirus, metapneumovirus, parainfluenza virus,… | 330 | $140 | $46.2K |
| 81226 | The lab analyst performs the technical lab test to detect the presence of common changes in the gene for cytochrome P450, family 2, subfamily D, polypeptide 6, also known as CYP2D6. | 100 | $440 | $43.8K |
| 82306 | The lab analyst measures the vitamin D level, typically on a serum specimen. This analyte, commonly known as vitamin D, is not really a vitamin, but is an important steroid hormone that is produced… | 1,450 | $30 | $42.1K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 1,460 | $30 | $36.5K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 1,480 | $20 | $34.1K |
| 81225 | The lab analyst performs the technical lab test to detect the presence of common changes in the gene for cytochrome P450, family 2, subfamily C, polypeptide 19, also known as CYP2C19. | 100 | $290 | $27.7K |
Showing 1–10 of 100
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 100 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
100 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| 81162 | 2 | 10 | 300 | $1,790 | $541K |
| 87798 | 25 | 40 | 740 | $30 | $218.3K |
| G0483 | 3 | 20 | 270 | $240 | $82.4K |
| 87581 | 6 | 10 | 350 | $30 | $64.6K |
| 87486 | 6 | 10 | 350 | $30 | $64.2K |
| K1034 | 1 | 1,800 | 730 | $10 | $60.3K |
| 81226 | 1 | 10 | 100 | $440 | $43.7K |
| 86235 | 20 | 40 | 650 | $20 | $33.6K |
| 86769 | 29 | 50 | 180 | $40 | $32.3K |
| 87637 | 32 | 70 | 30 | $140 | $31.4K |
Showing 1–10 of 100
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
159 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 12,900 | $100 | $1.3M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 22,720 | $50 | $1.1M |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 17,550 | $10 | $228.2K |
| 87631 | The lab analyst performs the technical steps to detect three to five types or subtypes of pathogens, such as adenovirus, influenza virus, coronavirus, metapneumovirus, parainfluenza virus,… | 4,470 | $40 | $165.4K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 17,660 | $10 | $123.6K |
| 82306 | The lab analyst measures the vitamin D level, typically on a serum specimen. This analyte, commonly known as vitamin D, is not really a vitamin, but is an important steroid hormone that is produced… | 4,360 | $20 | $74.1K |
| 80050 | The lab analyst performs testing for the specific group of clinical laboratory procedures in the general health panel. Payers typically consider 80050 to apply only when the clinician orders the… | 3,040 | $20 | $66.9K |
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 2,740 | $20 | $57.5K |
| 87635 | Using an amplified nucleic acid probe technique, the lab analyst performs the necessary steps to identify the nucleic acids from the severe acute respiratory syndrome coronavirus 2 (SARS–COV–2) virus… | 5,340 | $10 | $53.4K |
| 87633 | The lab analyst performs a test to identify a respiratory virus using amplified nucleic acid probe technique. He may also use a multiplex reverse transcription technique. The provider does this for… | 340 | $150 | $50K |
Showing 1–10 of 159
How this provider's Medicaid billing volume and revenue compare to other New York providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. New York median
159 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 44 | 340 | 1,090 | $70 | $1.4M |
| 81408 | The lab analyst performs the technical lab test to complete one of the specific genetic analyses listed in this Tier 2, Level 9 molecular pathology code. | 10 | 10 | 610 | $1,180 | $831.4K |
| 87633 | The lab analyst performs a test to identify a respiratory virus using amplified nucleic acid probe technique. He may also use a multiplex reverse transcription technique. The provider does this for… | 71 | 140 | 360 | $130 | $492.1K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 51 | 300 | 1,710 | $20 | $458.6K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 61 | 110 | 690 | $50 | $442K |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 147 | 290 | 1,900 | $30 | $390.6K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 4 | 30 | 550 | $100 | $359.8K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 21 | 20 | 240 | $70 | $302K |
| 86481 | The lab analyst performs a test to evaluate an antigen response to certain tuberculosis (TB) antibodies by enumerating T cells that produce gamma interferon. | 21 | 30 | 1,350 | $40 | $300.8K |
| 80053 | The lab analyst performs a comprehensive metabolic panel, or CMP test in which he measures the blood level of 14 chemicals the code descriptor lists for the panel. | 234 | 590 | 1,160 | $20 | $277.2K |
Showing 1–10 of 159
Other providers in the same ZIP code as Enigma Management Corp Dba Alliance Laboratory, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Nae Edison LLC | NY | Home Health Agency | $0 | $1.1B |
| Astra Home Care | NY | Home Health Agency | $0 | $608.7M |
| True Family Care Services, LLC | NY | Home Health Agency | $0 | $412.4M |
| Tradition Choice | NY | Home Health Agency | $0 | $207.9M |
| Asc Of New York, LLC | NY | Home Health Agency | $0 | $111M |
| Great Direct Care, Inc. | NY | Home Health Agency | $0 | $109M |
| Advanced Home Care Services, Inc. | NY | Home Health Agency | $0 | $99.3M |
| New Solution Home Care Inc | NY | Clinic/Center | $0 | $83.9M |
| Nurturing Direct Homecare, Inc | NY | Home Health Agency | $0 | $82.1M |
| Yeled V'yalda Early Childhood Center Inc. | NY | Early Intervention Provider Agency | $0 | $70M |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.